News Agency
Men's Weekly

Akeso's Cadonilimab (PD-1/CTLA-4) Phase III Trial Meets Primary Endpoint at Interim Analysis Demonstrating Strong Overall Survival Benefit as First-line Treatment in All-comer Patients with Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GE

  • Written by PR Newswire

HONG KONG, Nov. 7, 2023 /PRNewswire/ -- Akeso (9926.HK) announced positive results from an interim analysis of AK104-302 study, a randomized, double-blind, multicenter, phase III clinical study evaluating PD-1/CTLA-4 bispecific antibody, cadonilimab (开坦尼®) in combination with capecitabine plus oxaliplatin (XELOX) compared...

Read more: Akeso's Cadonilimab (PD-1/CTLA-4) Phase III Trial Meets Primary Endpoint at Interim Analysis...

Your Post-Study Work Visa Could Do More Than You Think — If You Use It Right

Completing your education in Australia is a great milestone, but every international graduate has to face the infamous: what's next? For some, the Temporary Graduate Visa (subclass 485) appears to be the next logical step as it allows you to... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion